Celularity (CELU) Retained Earnings (2018 - 2025)
Celularity (CELU) posted quarterly Retained Earnings of -$991.5 million for Q4 2025, down 209.13% year-over-year from $908.5 million in Q4 2024, and down 2.52% quarter-over-quarter from -$967.1 million in Q3 2025.
Celularity (CELU) Retained Earnings (2018 - 2025) Analysis & Trends
Celularity (CELU) has reported Retained Earnings for 8 consecutive years, with -$991.5 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Retained Earnings fell 209.13% year-over-year to -$991.5 million; the TTM figure through Dec 2025 stood at -$991.5 million (down 209.13% YoY), while the FY2025 annual figure was -$991.5 million, down 209.13% from the prior year.
- Retained Earnings slipped to -$991.5 million in Q4 2025 per CELU's latest filing, from -$967.1 million in the prior quarter.
- Across five years, Retained Earnings topped out at $914.0 million in Q1 2025 and bottomed at -$991.5 million in Q4 2025.
- Historically, Retained Earnings has averaged -$317.7 million across 5 years, with a median of -$669.2 million in 2021.
- Annual changes were most pronounced in 2022 — Retained Earnings surged 226.42% — and 2023, when it plunged 9353333.33%.
- Celularity's Retained Earnings stood at -$663.7 million in 2021, then jumped by 100.0% to $9000.0 in 2022, then slumped by 9353333.33% to -$841.8 million in 2023, then jumped by 207.93% to $908.5 million in 2024, then slumped by 209.13% to -$991.5 million in 2025.
- Business Quant data shows CELU's Retained Earnings at -$991.5 million in Q4 2025, -$967.1 million in Q3 2025, and -$944.0 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | Celularity | 20.99 Mn | 14.82 Mn | -3.27 Mn | -991.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -991.48 Mn |
| Sep 30, 2025 | -967.10 Mn |
| Jun 30, 2025 | -944.03 Mn |
| Mar 31, 2025 | 913.99 Mn |
| Dec 31, 2024 | 908.52 Mn |
| Sep 30, 2024 | -886.39 Mn |
| Jun 30, 2024 | 898.10 Mn |
| Mar 31, 2024 | -863.80 Mn |
| Dec 31, 2023 | -841.79 Mn |
| Sep 30, 2023 | -851.34 Mn |
| Jun 30, 2023 | -757.46 Mn |
| Mar 31, 2023 | 2.67 Mn |
| Dec 31, 2022 | 9,000.00 |
| Sep 30, 2022 | 833.92 Mn |
| Jun 30, 2022 | -674.73 Mn |
| Mar 31, 2022 | -722.55 Mn |
| Dec 31, 2021 | -663.68 Mn |
| Sep 30, 2021 | -659.64 Mn |
| Jun 30, 2021 | -47.41 Mn |
| Mar 31, 2021 | -39.58 Mn |